The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. ASGCT's strategic vision is to be a catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease. Join ASGCT in the heart of the biotech valley for the field's premier event, and take in the cutting edge of science with leaders from academia, medicine, industry, advocacy, and more.
Human Gene Therapy (HGT) is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes important advances in DNA, RNA, cell and immune therapies, validating the latest advances in research and new technologies.
The CRISPR Journal is the only peer-reviewed publication dedicated to the science and applications of gene editing. Spearheaded by Editor-in-Chief Rodolphe Barrangou, PhD and aided by a diverse and accomplished editorial board, the Journal provides a high-profile forum for cutting-edge international original research papers, as well as a compelling mixture of frontmatter content— review articles, perspectives, profiles, and commentary spanning not only matters of research but the many social, ethical, and business issues confronting the field.
Come visit us at booths #1321 & #1323 at the ASGCT 23rd Annual Meeting